相关实验视频

Updated: Jun 9, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

构建一个由瘤突变负担衍生的LncRNA预后计算框架,与皮肤皮肤黑色素瘤治疗敏感性相关

Gaohua Li¹, Tingting Wu², Heping Li¹

¹Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.

Journal of translational medicine

|October 25, 2024

概括

瘤突变负担衍生免疫 lncRNA预后指数 (TILPI) 显示了预测皮肤皮肤黑色素瘤 (SKCM) 的前景. 向STARD4-AS1和ADCY4/PRKACA/SOX10通路可能会抑制SKCM的进展.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物信息学是一种生物信息学.

背景情况:

皮肤皮肤黑色素瘤 (SKCM) 是一种具有有限治疗选择的侵袭性癌症.
为SKCM引入了一种新的预后指数TILPI.

研究的目的:

为SKCM开发和验证瘤突变负载衍生免疫 lncRNA预后指数 (TILPI).
阐明STARD4-AS1在SKCM进展中的作用.

主要方法:

基因组变异分析,差异表达分析和COX回归被用于开发TILPI.
功能实验评估了STARD4-AS1对SKCM细胞增殖,迁移,入侵和体内瘤生长的影响.

主要成果:

STARD4-AS1敲除显著降低了SKCM瘤细胞的增殖,迁移和入侵.
在基因和蛋白质水平上,Knockdown导致ADCY4,PRKACA和SOX10的下调.
在体内研究证实,通过STARD4-AS1敲击,瘤生长减少.

结论:

在SKCM的进展中,STARD4-AS1和ADCY4/PRKACA/SOX10通路至关重要.
结合实验验证的TILPI,提供了对SKCM预后和管理的见解.
像TILPI这样的计算框架有潜力通过准关键路径来预测和管理SKCM.

关键词:

在ADCY4/PRKACA/SOX10路径中.免疫的景观.在STARD4-AS1中进行了敲击.皮肤皮肤黑色素瘤瘤的突变负担

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.